Adjunctive Thrombolysis Doesn't Boost tPA Benefits
(MedPage Today) -- PHOENIX -- Adjunctive thrombolysis with either argatroban or eptifibatide for acute ischemic stroke did not boost efficacy and contributed to risk, the MOST trial showed. When given after starting alteplase (Activase) or tenecteplase... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 8, 2024 Category: Cardiology Source Type: news

Alteplase Not Harmful in NOAC Users, Even in a More Bleeding-Prone Cohort
(MedPage Today) -- Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to an Asian cohort study that... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 20, 2023 Category: Cardiology Source Type: news

Tenecteplase Non-inferior to Alteplase in Stroke: ATTEST-2 Tenecteplase Non-inferior to Alteplase in Stroke: ATTEST-2
This result, along with its ease of use, adds to the growing evidence that tenecteplase should be a first-line thrombolytic agent, trial investigators say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 21, 2023 Category: Cardiology Tags: Cardiology News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news

Tenecteplase a First-Line Thrombolytic for LVO Stroke? Tenecteplase a First-Line Thrombolytic for LVO Stroke?
Tenecteplase confers similar reperfusion, safety, and functional outcomes as alteplase in patients with large-vessel occlusion stroke, new research shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 12, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Tenecteplase Noninferior to Alteplase for Ischemic Stroke: TRACE-2 Tenecteplase Noninferior to Alteplase for Ischemic Stroke: TRACE-2
988192Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 13, 2023 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Dual Antiplatelet Therapy Proves Mettle in Minor Stroke
(MedPage Today) -- DALLAS -- Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute minor stroke who presented... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 13, 2023 Category: Cardiology Source Type: news

Tenecteplase on Par With Alteplase, Randomized Trial Affirms
(MedPage Today) -- DALLAS -- Tenecteplase (TNKase) did as good a job at ischemic stroke thrombolysis as did alteplase (Activase) for patients presenting within 4.5 hours of symptom onset in the randomized TRACE-2 trial from China. The proportion... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 9, 2023 Category: Cardiology Source Type: news

Tenecteplase Versus Alteplase in Routine Clinical Practice Tenecteplase Versus Alteplase in Routine Clinical Practice
This paper details the results of a hospital network ' s transition from alteplase to tenecteplase as the standard of care for stroke thrombolysis. How did costs and clinical outcomes compare?Stroke (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Combo Thrombolytic Approach Fails to Reduce ICH in Stroke Combo Thrombolytic Approach Fails to Reduce ICH in Stroke
The DUMAS study showed no benefit on the primary outcome of all ICH with low-dose alteplase followed by mutant pro-urokinase; but there were promising signs of a potential reduced bleeding risk.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 2, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andT...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follic...
Source: Roche Media News - July 21, 2022 Category: Pharmaceuticals Source Type: news